Recent news coverage does not directly pertain to Regen BioPharma Inc but includes general market and sector updates from August 2026.

• Recent news items primarily cover other companies' earnings and market movements, with no direct updates on Regen BioPharma Inc's operations or developments [N1][N2][N3][N4][N5][N6][N7][N8].

The company holds a diverse pipeline of regenerative medicine therapies with proprietary technologies targeting significant unmet medical needs such as aplastic anemia and cancer. Its patents on gene silencing and immune modulation could provide competitive advantages if clinical development progresses. Licensing agreements with upfront fees and royalties offer potential revenue sources. The planned Phase I clinical trial for HemaXellarate represents a key milestone in demonstrating safety and potential efficacy.

Regen BioPharma has not initiated clinical trials for its product candidates, limiting evidence of efficacy or commercial viability. The company faces significant liquidity constraints, with a current ratio of 0.05 and net losses reported. Its reliance on licensing revenue and the need for successful clinical development pose execution risks. The absence of broad market or industry data and limited recent news coverage reduce external visibility and may impact investor confidence.

Regen BioPharma's moat lies in its portfolio of patented intellectual property covering novel gene silencing technologies, immune checkpoint modulation, and cancer vaccine platforms. Its licensing agreements with other entities for veterinary and human therapeutic development provide potential revenue streams. However, the company has not yet commenced clinical trials for its product candidates, and its financial position shows limited liquidity and ongoing net losses, which may constrain its ability to advance development independently.

• Clinical Development Risk: No clinical trials have commenced on product candidates, so safety and efficacy remain unproven.
• Financial Risk: The company has limited liquidity with a current ratio of 0.05 as of June 30, 2026, and reported net losses, which may impact its ability to fund operations.
• Execution Risk: Advancing therapies through clinical phases and securing successful licensing or commercialization agreements are critical and uncertain.
• Dependence on Licensing Revenue: Revenue depends on license agreements and royalties, which may fluctuate and are subject to licensee performance.

• Regen BioPharma Inc is incorporated in Nevada since April 24, 2012.
• The company focuses on developing regenerative medical applications, aiming to license, develop internally, or acquire therapies up to successful completion of Phase I or II clinical trials.
• Post Phase I/II, the company may sell, license, or advance applications to Phase III trials based on efficacy indications.
• Therapies in development include HemaXellarate (autologous stromal vascular fraction for aplastic anemia), dCellVax (autologous dendritic cells treated with siRNA targeting IDO for cancer), tCellVax (immune cells treated with siRNA targeting NR2F6), DiffronC (siRNA targeting NR2F6 to inhibit cancer growth and activate T cells), DuraCar (CAR-T cells treated with shRNA targeting NR2F6), and small molecule NR2F6 modulators.
• No clinical trials have commenced on product candidates; no efficacy conclusions are made.
• The company controls intellectual property including patents on gene silencing of BORIS, methods for generating IL-17 associated antitumor cells by NR2F6 inhibition, screening compounds modulating NR2F6, modulation of NR2F6, universal donor checkpoint inhibitor silenced cord blood killer cells, antigen specific mRNA cancer vaccines, siRNA silencing for cancer treatment, and small molecule agonists/antagonists of NR2F6.
• Regen Biopharma has license agreements with Zander Therapeutics for non-human veterinary therapeutic use and with Oncology Pharma for human pancreatic and colon cancer treatments, involving upfront fees, royalties, and sublicensing revenue.
• The company recognizes royalty revenue based on contractual agreements and estimates of licensee sales.
• Research and development costs are expensed as incurred; recent R&D costs were $2,216 for Q1 2026 and $212,216 for the six months ended March 31, 2026.
• As of June 30, 2026, cash and equivalents were $239,000; current assets were $287,587; current liabilities were $6,165,793, resulting in a current ratio of 0.05 and a cash ratio of 0.
• Net income for the quarter ended June 30, 2026 was a loss of $637,785; basic and diluted EPS were $0.
• Accrued expenses increased due to payroll tax liabilities related to issuance of 20 million common shares to the CEO for services related to a planned Phase I clinical trial of HemaXellarate.
• Unearned income relates to payments under license agreements recognized over the terms of the agreements.